Trial Profile

Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects With Homozygous Familial Hypercholesterolemia (HOFH)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 14 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Zodasiran (Primary)
Indications Hyperlipoproteinaemia type II
Focus Therapeutic Use
Acronyms Gateway
Sponsors Arrowhead Pharmaceuticals

Most Recent Events

22 May 2026 Status changed from active, no longer recruiting to discontinued.
10 Oct 2025 Planned End Date changed from 1 May 2025 to 1 Nov 2025.
23 May 2023 According to an Arrowhead Pharmaceuticals media release, data were presented at the 91st European Atherosclerosis Society Congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com